Abstract:Based on the results of computational docking to the active site of the cytochrome P450 14α-demethylase (CYP51), a series of 1-(1H-1,2,4-triazole-1-yl)-2-(2,4-difluorophenyl)-3-substituted-2-propanols as analogs of fluconazole were designed, synthesized, and evaluated as antifungal agents. The MIC80 values indicate that compounds 1a–n exhibited higher activity against nearly all fungi tested except Aspergillus fumigatus than fluconazole, while compounds 2a–f, 3a–f showed no activity or only moderate activity against all fungi tested. Noticeably, the MIC value of compounds 1a, 1b and 1g is 64 times lower than that of fluconazole against Microsporum gypseum in vitro. And compounds 1a, 1b and 2b showed 128 times higher activity (with the MIC80 value of 0.0039μg/mL) than that of fluconazole against Candida albicans and also showed higher activity than that of the other positive controls. Computational docking experiments indicated that the inhibition of CYP51 involves a coordination bond with iron of the heme group, the hydrophilic H-bonding region, the hydrophobic region, and the narrow hydrophobic cleft. In addition, the activity of the compounds would be enhanced when the side chains were shorter.

Design, synthesis, and antifungal activity of novel conformationally restricted triazole derivatives.

Structure-based design, synthesis, and antifungal activity of new triazole derivatives.

Design, Synthesis, and Antifungal Activities of Novel 1H-Triazole Derivatives Based on the Structure of the Active Site of Fungal Lanosterol 14α-Demethylase (CYP51)

Design, synthesis, and antifungal activities of novel 1H-triazole derivatives based on the structure of the active site of fungal lanosterol 14 alpha-demethylase (CYP51).

Design, synthesis and antifungal activities of novel 1,2,4-triazole derivatives.

Synthesis, in Vitro Evaluation and Molecular Docking Studies of New Triazole Derivatives As Antifungal Agents.

Novel conformationally restricted triazole derivatives with potent antifungal activity.

Molecular Docking, Design, Synthesis and Antifungal Activity Study of Novel Triazole Derivatives Containing the 1,2,3-Triazole Group

Design, synthesis and in vitro biological studies of novel triazoles with potent and broad-spectrum antifungal activity

Design, Synthesis and Molecular Docking Studies of Novel Triazole Antifungal Compounds

Design, synthesis and antifungal activity of novel triazole derivatives containing substituted 1,2,3-triazole-piperdine side chains.

Design, synthesis and molecular docking studies of novel triazole as antifungal agent.

Design, synthesis and <i>in vitro</i> biological studies of novel triazoles with potent and broad-spectrum antifungal activity

Design, Synthesis, and Biological Evaluation of Novel Triazole Derivatives As Inhibitors of Cytochrome P450 14Α-Demethylase.

Synthesis of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase (CYP51).

Design, synthesis, and in vitro evaluation of novel antifungal triazoles containing substituted 1,2,3-triazole-methoxyl side chains

Design, Synthesis, and in Vitro Evaluation of Novel Triazole Analogues Featuring Isoxazole Moieties As Antifungal Agents.

Design, Synthesis and Antifungal Evaluation of 1-(2-(2,4-Difluorophenyl)-2-hydroxy-3-(1h-1,2,4-triazol-1-yl)propyl)-1h-1,2,4-triazol-5(4h)-one

Synthesis, antifungal activity, and molecular docking studies of novel triazole derivatives.

Synthesis, In Vitro Biological Evaluation, and Molecular Docking of New Triazoles as Potent Antifungal Agents.

New Triazole Derivatives Containing Substituted 1,2,3-Triazole Side Chains: Design, Synthesis and Antifungal Activity